Tuberculosis and Respiratory Diseases

  • 제83권3호
  • /
  • Pages.185-194
  • /
  • 2020
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects

  • Singh, Dave (Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester University NHS Hospital Trust)
  • 투고 : 2020.03.20
  • 심사 : 2020.04.10
  • 발행 : 2020.07.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Blood eosinophil counts have emerged as a chronic obstructive pulmonary disease (COPD) biomarker that predict the effects of inhaled corticosteroids (ICS) in clinical practice. Post-hoc and prospective analysis of randomized control trials have shown that higher blood eosinophil counts at the start of the study predict a greater response to ICS. COPD patients with frequent exacerbations (2 or more moderate exacerbations/yr) or a history of hospitalization have a greater response to ICS. Ex-smokers also appear to have a greater ICS response. Blood eosinophil counts can be combined with clinical information such as exacerbation history and smoking status to enable a precision medicine approach to the use of ICS. Higher blood eosinophil counts are associated with increased eosinophilic lung inflammation, and other biological features that may contribute to the increased ICS response observed. Emerging data indicates that lower blood eosinophil counts are associated with an increased risk of bacterial infection, suggesting complex relationships between eosinophils, ICS response, and the airway microbiome.

키워드

참고문헌

  1. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J 2017;49:1700214. https://doi.org/10.1183/13993003.00214-2017
  2. Singh D, Roche N, Halpin D, Agusti A, Wedzicha JA, Martinez FJ. Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2016;194:541-9. https://doi.org/10.1164/rccm.201606-1179PP
  3. Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J 2019;53:1900164. https://doi.org/10.1183/13993003.00164-2019
  4. Singh D, Corradi M, Spinola M, Petruzzelli S, Papi A. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Prim Care Respir Med 2016;26:16030. https://doi.org/10.1038/npjpcrm.2016.30
  5. Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016;388:963-73. https://doi.org/10.1016/S0140-6736(16)31354-X
  6. Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus longacting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017;389:1919-29. https://doi.org/10.1016/S0140-6736(17)30188-5
  7. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018;391:1076-84. https://doi.org/10.1016/s0140-6736(18)30206-x
  8. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;378:1671-80. https://doi.org/10.1056/NEJMoa1713901
  9. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38. https://doi.org/10.1056/NEJMoa0909883
  10. Esnault S, Kelly EA. Essential mechanisms of differential activation of eosinophils by IL-3 compared to GM-CSF and IL-5. Crit Rev Immunol 2016;36:429-44.
  11. Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koeter GH, Postma DS. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000;15:109-15. https://doi.org/10.1183/09031936.00.15110900
  12. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:39-47.
  13. Kolsum U, Southworth T, Jackson N, Singh D. Blood eosinophil counts in COPD patients compared to controls. Eur Respir J 2019;54:1900633. https://doi.org/10.1183/13993003.00633-2019
  14. Kolsum U, Damera G, Pham TH, Southworth T, Mason S, Karur P, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol 2017;140:1181-4. https://doi.org/10.1016/j.jaci.2017.04.027
  15. Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol 2015;15:57-65. https://doi.org/10.1038/nri3786
  16. Bush A. How early do airway inflammation and remodeling occur? Allergol Int 2008;57:11-9. https://doi.org/10.2332/allergolint.R-07-155
  17. Kolsum U, Ravi A, Hitchen P, Maddi S, Southworth T, Singh D. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res 2017;18:73. https://doi.org/10.1186/s12931-017-0559-0
  18. Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med 2017;5:956-67. https://doi.org/10.1016/S2213-2600(17)30432-0
  19. Bafadhel M, McKenna S, Pickering S, Reid C, Mistry V, Rugman P, et al. The sensitivity and specificity of peripheral blood eosinophilia to predict sputum eosinophilia in COPD subjects. Am J Respir Crit Care Med 2009;179:A1479.
  20. Pignatti P, Visca D, Cherubino F, Zampogna E, Lucini E, Saderi L, et al. Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients. Respir Res 2019;20:145. https://doi.org/10.1186/s12931-019-1111-1
  21. Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J 2014;44:1697-700. https://doi.org/10.1183/09031936.00162414
  22. Negewo NA, McDonald VM, Baines KJ, Wark PA, Simpson JL, Jones PW, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis 2016;11:1495-504. https://doi.org/10.2147/COPD.S100338
  23. Eltboli O, Mistry V, Barker B, Brightling CE. Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology 2015;20:667-70. https://doi.org/10.1111/resp.12475
  24. Turato G, Semenzato U, Bazzan E, Biondini D, Tine M, Torrecilla N, et al. Blood eosinophilia neither reflects tissue eosinophils nor worsens clinical outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018;197:1216-9. https://doi.org/10.1164/rccm.201708-1684LE
  25. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193-8. https://doi.org/10.1136/thx.2004.032516
  26. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-5. https://doi.org/10.1016/S0140-6736(00)02872-5
  27. Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018;6:117-26. https://doi.org/10.1016/S2213-2600(18)30006-7
  28. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435-42. https://doi.org/10.1016/S2213-2600(15)00106-X
  29. Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523-5. https://doi.org/10.1164/rccm.201502-0235LE
  30. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med 2019;7:745-56. https://doi.org/10.1016/s2213-2600(19)30190-0
  31. Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018;6:747-58. https://doi.org/10.1016/S2213-2600(18)30327-8
  32. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222-34. https://doi.org/10.1056/NEJMoa1516385
  33. Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME Trial. Am J Respir Crit Care Med 2017;195:1189-97. https://doi.org/10.1164/rccm.201701-0193OC
  34. Singh D. Double combination inhalers in COPD: how to get your head around this data. Respirology 2018;23:1088-9. https://doi.org/10.1111/resp.13422
  35. Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, doubleblind, triple-dummy clinical trial. Am J Respir Crit Care Med 2018;198:329-39. https://doi.org/10.1164/rccm.201803-0405oc
  36. Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4:390-8. https://doi.org/10.1016/S2213-2600(16)00100-4
  37. Calverley PM, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EF, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196:1219-21. https://doi.org/10.1164/rccm.201612-2525LE
  38. Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285-94. https://doi.org/10.1056/NEJMoa1407154
  39. Voorham J, Corradi M, Papi A, Vogelmeier CF, Singh D, Fabbri LM, et al. Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Res 2019;5:00106-2019.
  40. Southworth T, Beech G, Foden P, Kolsum U, Singh D. The reproducibility of COPD blood eosinophil counts. Eur Respir J 2018;52:1800427. https://doi.org/10.1183/13993003.00427-2018
  41. Long GH, Southworth T, Kolsum U, Donaldson GC, Wedzicha JA, Brightling CE, et al. The stability of blood eosinophils in chronic obstructive pulmonary disease. Respir Res 2020;21:15. https://doi.org/10.1186/s12931-020-1279-4
  42. Barker B, Mistry V, Pancholi M, Brightling C, Bafadhel M. P210: are sputum and blood biomarkers of inflammation repeatable in stable COPD? Thorax 2012;67:A155-6.
  43. Landis SH, Suruki R, Hilton E, Compton C, Galwey NW. Stability of blood eosinophil count in patients with COPD in the UK clinical practice research datalink. COPD 2017;14:382-8. https://doi.org/10.1080/15412555.2017.1313827
  44. Bafadhel M, Pavord ID, Russell RE. Eosinophils in COPD: just another biomarker? Lancet Respir Med 2017;5:747-59. https://doi.org/10.1016/S2213-2600(17)30217-5
  45. Casanova C, Celli BR, de-Torres JP, Martinez-Gonzalez C, Cosio BG, Pinto-Plata V, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J 2017;50:1701162. https://doi.org/10.1183/13993003.01162-2017
  46. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [Internet]. Fontana, WI: The Global Initiative for Chronic Obstructive Lung Disease; 2020 [cited 2020 Jan 10]. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosismanagement.html.
  47. Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018;141:2037-47. https://doi.org/10.1016/j.jaci.2018.04.010
  48. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med 2016;193:965-74. https://doi.org/10.1164/rccm.201509-1869OC
  49. DiSantostefano RL, Hinds D, Le HV, Barnes NC. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. Respir Med 2016;112:88-96. https://doi.org/10.1016/j.rmed.2016.01.013
  50. Coleman JM, Naik C, Holguin F, Ray A, Ray P, Trudeau JB, et al. Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age at onset. Thorax 2012;67:1061-6. https://doi.org/10.1136/thoraxjnl-2012-201634
  51. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-36. https://doi.org/10.1172/JCI17974
  52. Christenson SA, Steiling K, van den Berge M, Hijazi K, Hiemstra PS, Postma DS, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;191:758-66. https://doi.org/10.1164/rccm.201408-1458OC
  53. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-95. https://doi.org/10.1164/rccm.200903-0392OC
  54. Bateman ED, Reddel HK, van Zyl-Smit RN, Agusti A. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med 2015;3:719-28. https://doi.org/10.1016/S2213-2600(15)00254-4
  55. Maselli DJ, Hardin M, Christenson SA, Hanania NA, Hersh CP, Adams SG, et al. Clinical approach to the therapy of asthma-COPD overlap. Chest 2019;155:168-77. https://doi.org/10.1016/j.chest.2018.07.028
  56. Kolsum U, Donaldson GC, Singh R, Barker BL, Gupta V, George L, et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir Res 2017;18:88. https://doi.org/10.1186/s12931-017-0570-5
  57. Contoli M, Pauletti A, Rossi MR, Spanevello A, Casolari P, Marcellini A, et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J 2017;50:1700451. https://doi.org/10.1183/13993003.00451-2017
  58. Martinez-Garcia MA, Faner R, Oscullo G, la Rosa-Carrillo D, Soler-Cataluna JJ, Ballester M, et al. Inhaled steroids, circulating eosinophils, chronic airway infection and pneumonia risk in chronic obstructive pulmonary disease: a network analysis. Am J Respir Crit Care Med 2020 Jan 10 [Epub]. https://doi.org/10.1164/rccm.201908-1550OC.
  59. Dransfield MT, Singh D. Predicting pneumonia in COPD: have we unraveled the network of risks? Am J Respir Crit Care Med 2020 Feb 3 [Epub]. https://doi.org/10.1164/rccm.202001-0132ED.
  60. George L, Wright A, Mistry V, Sutcliffe A, Chachi L, Haldar K, et al. Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab. Int J Chron Obstruct Pulmon Dis 2019;14:1177-85. https://doi.org/10.2147/COPD.S198302
  61. Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J 2016;47:1082-92. https://doi.org/10.1183/13993003.01406-2015
  62. Ghebre MA, Pang PH, Diver S, Desai D, Bafadhel M, Haldar K, et al. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. J Allergy Clin Immunol 2018;141:2027-36. https://doi.org/10.1016/j.jaci.2018.04.013
  63. Wang Z, Maschera B, Lea S, Kolsum U, Michalovich D, Van Horn S, et al. Airway host-microbiome interactions in chronic obstructive pulmonary disease. Respir Res 2019;20:113. https://doi.org/10.1186/s12931-019-1085-z
  64. Singh D, Siew L, Christensen J, Plumb J, Clarke GW, Greenaway S, et al. Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects. Eur J Clin Pharmacol 2015;71:1175-84. https://doi.org/10.1007/s00228-015-1920-1
  65. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-43. https://doi.org/10.1164/rccm.200508-1321OC
  66. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007;62:938-43. https://doi.org/10.1136/thx.2006.071068
  67. Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, et al. Benralizumab for the prevention of COPD Exacerbations. N Engl J Med 2019;381:1023-34. https://doi.org/10.1056/NEJMoa1905248
  68. Pavord ID, Chanez P, Criner GJ, Kerstjens HA, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med 2017;377:1613-29. https://doi.org/10.1056/NEJMoa1708208
  69. Criner GJ, Celli BR, Singh D, Agusti A, Papi A, Jison M, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med 2020;8:158-70. https://doi.org/10.1016/s2213-2600(19)30338-8
  70. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71. https://doi.org/10.1164/rccm.201104-0597OC
  71. Mayhew D, Devos N, Lambert C, Brown JR, Clarke SC, Kim VL, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax 2018;73:422-30. https://doi.org/10.1136/thoraxjnl-2017-210408
  72. Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FM, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J 2018;52:1801219. https://doi.org/10.1183/13993003.01219-2018

피인용 문헌

  1. Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study vol.16, 2020, https://doi.org/10.2147/copd.s332151
  2. Using Blood Eosinophil Count as a Biomarker to Guide Corticosteroid Treatment for Chronic Obstructive Pulmonary Disease vol.11, pp.2, 2020, https://doi.org/10.3390/diagnostics11020236
  3. Pharmacological treatment of stable chronic obstructive pulmonary disease vol.26, pp.7, 2020, https://doi.org/10.1111/resp.14046
  4. Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update vol.15, pp.9, 2020, https://doi.org/10.1080/17476348.2021.1920403
  5. Neutrophil-to-lymphocyte ratio, blood eosinophils and COPD exacerbations: a cohort study vol.7, pp.4, 2021, https://doi.org/10.1183/23120541.00471-2021